Trials / Terminated
TerminatedNCT05492045
A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer
A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 Combination Therapy in Subjects With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- InventisBio Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 Combination Therapy in Subjects with KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | D-1553 | D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation. |
| DRUG | Other | Standard treatment of NSCLC. |
Timeline
- Start date
- 2022-09-13
- Primary completion
- 2024-06-14
- Completion
- 2024-06-14
- First posted
- 2022-08-08
- Last updated
- 2024-10-15
Locations
2 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05492045. Inclusion in this directory is not an endorsement.